Apogee Therapeutics Option Alert: Aug 15 $35 Puts at the Bid: 1000 vs 201 OI; Earnings 8/11 Before Open [est] 

Apogee Therapeutics Option Alert: Aug 15 $35 Puts at the Bid: 1000 @ $7.0 vs 201 OI; Earnings 8/11 Before Open [est] Ref=$43.26

Apogee Therapeutics 株価情報 (NASDAQ: APGE)

Apogee Therapeutics (NASDAQ:APGE) 株価情報

APOGEE THERAPEUTICS INC

Apogee Therapeutics

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Apogee Therapeutics Inc

News

Garrett Motion Added To Russell 2000 Index

Logistic Properties Of The Americas Joins Russell 3000 And Russell Microcap Indexes

NextPlat Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPL#NASDAQ">NXPL</a>, NXPLW)), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through eCommerce and retail channels worldwide, today issued the following Interim CEO Update Shareholder Letter:
To Our Shareholders:
As interim CEO of NextPlat and on behalf of our Board of Directors and management team, I am writing to you to provide an update on our company and the actions being taken to drive the business forward.
In the month since the unexpected passing of our former CEO and Chairman, Charles M. Fernandez, our team has been closely reviewing our operations to build on the strong foundation he helped create. As part of this, I personally met with leaders across our subsidiaries and was truly impressed by the passion and dedication of our highly experienced employees. Based on the insights I gathered, I'm confident that with greater focus, improved coordination, and targeted investment, NextPlat is well-positioned to capitalize on the opportunities ahead and unlock significant value.
Where We Are Today
Having completed my initial review, I believe that our healthcare division is particularly critical to our future success as it currently represents the largest part of our business and offers significant untapped opportunities to explore. I believe there are several areas that we need to address if we are to properly support the business and reach our long-term goals, foremost amongst them being:
<ul>
<li>Continued operational process efficiency and cost reduction efforts to drive maximum&nbsp;ROI</li>
<li>Ensuring that we have the necessary talent leading our units and that they are empowered to manage and drive growth</li>
<li>Renewing a commitment to prudently invest in the business to help capitalize on growth opportunities, both organic and non-organic, while enhancing&nbsp;cashflow and long-term profitability</li>
</ul>
Where We Are Going – Pharmacy and Healthcare
As we've previously communicated, the retail pharmacy sector continues to face unprecedented challenges driven by rising drug costs and made worse by reimbursement rates not keeping pace with those rising costs. Therefore, our focus must remain on executing the business of the Company efficiently and investing in alternative areas of healthcare that offer growth potential.
To that end, we've been working to streamline our current healthcare operations and expand our contracted 340B and long-term care (LTC) services, both of which present opportunities for profitable growth. We also intend to take several strategic steps within our healthcare business, including:
<ul>
<li>Adding experienced healthcare leadership to the team to drive growth and enhance the daily management and profitability of the business</li>
<li>Expanding into new, high growth/high margin healthcare services through joint ventures and partnerships</li>
<li>Implementing a number of process and technology improvements designed to drive additional operational efficiencies, improve compliance, and attract a new customer demographic</li>
<li>Make further investments into marketing and sales programs targeting 340B and&nbsp;LTC providers, including the exploration of obtaining licenses in nearby southeastern states where additional 340B opportunities exist</li>
<li>Adding complementary services such as compounding, additional OTC products, and exploring opportunities such as opening in-house pharmacies</li>
<li>Pursuing special accreditation to enable us to dispense specialty medications, potentially leading to broader patient access and increased prescription volume on high margin sales</li>
<li>Begin targeting the non-insured (cash) sales market to diversify revenue streams and reduce dependence on insurance reimbursements</li>
<li>Evaluate opportunities for nationwide licensing to enable&nbsp;e-Commerce mail-order sales</li>
<li>Improving customer service responsiveness, access and support</li>
</ul>
Where We Are Going - E-Commerce
Although e-Commerce represents a smaller part of NextPlat's overall business, I have spoken in the past about the vast global opportunity and potential we see in this business. Through leading e-Commerce marketplaces such as Amazon.com, Walmart, and Alibaba in China, as well as our own network of branded online storefronts, we have created a global presence supporting tens of thousands of customers in over 150 countries. This is something we intend to build on.
Recently, new tariffs, particularly between the U.S. and China, have delayed product launches like our Florida Sunshine vitamin brand, but we still see strong global opportunities ahead. That is why we are focusing on growing our e-Commerce business through a series of initiatives including:
<ul>
<li>Further scaling our global&nbsp;e-Commerce presence through small, opportunistic acquisitions that bring accretive sales, distribution and potentially, valuable contracts and customer lists</li>
<li>Launching new international marketplaces, forming new distribution partnerships, and introducing new products and services to further expand our global customer base</li>
<li>Advance our recently launched storefront design and product management service for hardware manufacturers and connectivity services providers, helping them to build, optimize, and grow their brands in the world's largest online marketplaces and reach new customers.</li>
<li>Expanding our&nbsp;e-Commerce partnership with OPKO Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) ("OPKO") for sales into China of its health, nutrition, and dietary supplement products, adding unique animal care products later this year, all of which are not subject to any current tariffs</li>
<li>Continuing to explore opportunities to launch our Florida Sunshine vitamin brand in the UK and&nbsp;EU, following a setback of this project as a result of Chinese tariffs.</li>
</ul>
For Our Shareholders
As I indicated earlier in this update, the team at NextPlat shares a common belief in the long-term opportunities ahead of us and the ability to build upon the strong foundation created under Charlie's leadership. Our internal business review identified our strengths as well as areas that need immediate attention and improvement if we are to meet our growth and profitability objectives. That is why we are committed to addressing several areas and needs in the business, including:
<ul>
<li>Accelerating ongoing efforts to maximize efficiencies across the organization with the bottom-line goal of generating positive operating results and&nbsp;ROI</li>
<li>Investing in our operations and our people to profitably expand and grow the business</li>
<li>Fill gaps in our team and empower our leaders to execute against their respective growth plans</li>
<li>Implement the stock buyback program previously announced</li>
<li>Continue to improve shareholder transparency and engagement including outreach to the broader investor community</li>
</ul>
A Thank You
In conclusion, we must thank our partners, customers, employees, and investors for their continued support and wish to confirm our pledge that we&nbsp;intend to use recent developments as a catalyst for change and as an opportunity to advance Charlie's legacy. Although we have challenges ahead, Charlie created a strong and well-funded foundation for us to build on, and both I and our Board are committed to realizing and surpassing the potential he saw for NextPlat in the months and years ahead.
Sincerely,
David Phipps Interim Chief Executive Officer

NXPL

NextPlat Interim CEO  Issues Shareholder Letter Outlining Strategic Vision For Growth In Healthcare And E-Commerce

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>), a clinical-stage company focused on oncology and obesity, today announced the initiation of the multiple ascending dose (MAD) portion of its Phase 1 trial for CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. This follows safety and pharmacokinetics (PK) data analysis of the single ascending dose (SAD) study launched in March. The MAD portion of this clinical study is scheduled for completion in the third quarter of this year.
The MAD portion of the Phase 1 trial is designed to test a once-daily dosing of CRB-913 for 7 days. Similarly to the SAD study, the MAD study is undertaken with healthy volunteers and focuses on safety, tolerability and PK of increasing doses of CRB-913. The study is being conducted in the United States.
The SAD/MAD portion of the Phase 1 trial is scheduled to be completed in Q3 of 2025, and the Company expects to commence a Phase 1b dose-range finding study in Q4 of 2025. The dose-range finding study is scheduled for completion in the second half of 2026.

CRBP

Corbus Pharma Initiates Multiple Ascending Dose Portion Of Phase 1 Trial For CRB-913, Peripherally Restricted CB1 Inverse Agonist For Obesity Treatment; MAD Study On Track For Completion In Q3 2025

<h3>Gainers</h3>
<ul>
<li>Genius Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) stock increased by 13.7% to $1.12 during Monday's pre-market session. The company's market cap stands at $70.4 million. </li>
<li>Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) stock increased by 10.45% to $0.78. The company's market cap stands at $76.4 million. </li>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) stock increased by 9.9% to $1.22. The market value of their outstanding shares is at $18.1 million. </li>
<li>Cenntro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENN#NASDAQ">CENN</a>) stock moved upwards by 9.71% to $0.78. The company's market cap stands at $21.9 million. </li>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) shares moved upwards by 9.38% to $0.99. The company's market cap stands at $17.3 million. </li>
<li>Tokyo Lifestyle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKLF#NASDAQ">TKLF</a>) stock moved upwards by 8.33% to $4.03. The market value of their outstanding shares is at $157.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Emerson Radio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MSN#AMEX">MSN</a>) shares declined by 39.7% to $0.23 during Monday's pre-market session. The market value of their outstanding shares is at $8.1 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Cheetah Net Supply Chain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) shares fell 5.67% to $1.25. The company's market cap stands at $4.2 million. </li>
<li>Dogness (Intl) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOGZ#NASDAQ">DOGZ</a>) stock decreased by 5.23% to $27.05. The market value of their outstanding shares is at $406.1 million. </li>
<li>Yoshiharu Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YOSH#NASDAQ">YOSH</a>) shares declined by 5.1% to $8.92. The market value of their outstanding shares is at $16.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CENN

CTNT

DOGZ

GDHG

PRPL

TKLF

YOSH

10 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) stock moved upwards by 165.2% to $18.01 during Monday's pre-market session. The company's market cap stands at $3.7 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares rose 41.64% to $1.02. The company's market cap stands at $26.2 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock rose 25.68% to $2.74. The market value of their outstanding shares is at $4.0 million. </li>
<li>Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) shares increased by 22.68% to $1.99. The market value of their outstanding shares is at $120.4 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock moved upwards by 22.04% to $11.57. The market value of their outstanding shares is at $246.6 million. </li>
<li>Q32 Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTTB#NASDAQ">QTTB</a>) shares rose 14.48% to $1.66. The market value of their outstanding shares is at $17.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) shares fell 57.4% to $2.27 during Monday's pre-market session. The market value of their outstanding shares is at $124.6 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) shares fell 31.06% to $2.82. The market value of their outstanding shares is at $154.0 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock declined by 20.4% to $1.6. The market value of their outstanding shares is at $5.5 million. </li>
<li>Odysight ai (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODYS#NASDAQ">ODYS</a>) shares decreased by 20.12% to $5.6. The market value of their outstanding shares is at $114.3 million. </li>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) stock declined by 16.92% to $5.65. The company's market cap stands at $82.0 million. </li>
<li>MEI Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEIP#NASDAQ">MEIP</a>) shares decreased by 16.08% to $2.35. The market value of their outstanding shares is at $18.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

ARTL

INMB

KLTO

LIMN

MEIP

ODYS

QTTB

SERA

UNCY

VERO

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) shares increased by 128.6% to $4.0 during Monday's pre-market session. The market value of their outstanding shares is at $3.6 million. </li>
<li>Momentus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) stock moved upwards by 38.29% to $1.95. The market value of their outstanding shares is at $8.8 million. </li>
<li>Laser Photonics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>) shares increased by 22.82% to $2.95. The market value of their outstanding shares is at $36.6 million. </li>
<li>Globavend Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) stock rose 16.39% to $0.15. The market value of their outstanding shares is at $1.9 million. </li>
<li>Tecogen (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TGEN#AMEX">TGEN</a>) stock rose 15.84% to $8.28. The company's market cap stands at $180.6 million. </li>
<li>Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) stock rose 13.84% to $25.25. The company's market cap stands at $5.1 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>JVSPAC Acquisition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JVSA#NASDAQ">JVSA</a>) shares fell 52.4% to $5.09 during Monday's pre-market session. The market value of their outstanding shares is at $82.2 million. </li>
<li>Fortive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) shares decreased by 24.59% to $54.0. The market value of their outstanding shares is at $24.3 billion. </li>
<li>Babcock &amp; Wilcox Enterprises, Inc. 6.50% Senior Notes due 2026 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWNB#NYSE">BWNB</a>) shares decreased by 13.89% to $13.96. </li>
<li>Shoals Technologies Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) shares fell 13.32% to $4.1. The company's market cap stands at $790.7 million. </li>
<li>Nextracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) shares decreased by 9.9% to $52.55. The market value of their outstanding shares is at $8.7 billion. </li>
<li>Silynxcom (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SYNX#AMEX">SYNX</a>) shares fell 6.33% to $1.63. The company's market cap stands at $11.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BWNB

IPDN

JVSA

LASE

MNTS

SHLS

SYNX

TGEN

12 Industrials Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>BitMine Immersion Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#AMEX">BMNR</a>) shares rose 41.1% to $6.02 during Monday's pre-market session. The company's market cap stands at $25.8 million. </li>
<li>Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) stock increased by 14.06% to $21.0. The company's market cap stands at $24.1 billion. </li>
<li>3 E Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASK#NASDAQ">MASK</a>) shares increased by 12.56% to $2.5. The company's market cap stands at $24.9 million. </li>
<li>Mobix Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) shares increased by 11.03% to $0.84. The company's market cap stands at $40.6 million. </li>
<li>Wetouch Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETH#NASDAQ">WETH</a>) shares rose 9.09% to $1.08. The company's market cap stands at $11.8 million. </li>
<li>X3 Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) stock moved upwards by 8.9% to $1.59. The company's market cap stands at $52.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Argo Blockchain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) shares declined by 44.7% to $0.2 during Monday's pre-market session. The market value of their outstanding shares is at $23.1 million. </li>
<li>Locafy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCFY#NASDAQ">LCFY</a>) shares declined by 19.4% to $6.69. The market value of their outstanding shares is at $10.5 million. </li>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) stock decreased by 14.43% to $2.73. The company's market cap stands at $1.4 million. </li>
<li>Ostin Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) stock fell 14.19% to $0.3. The company's market cap stands at $37.5 million. </li>
<li>ChipMOS TECHNOLOGIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMOS#NASDAQ">IMOS</a>) stock fell 10.92% to $16.49. The market value of their outstanding shares is at $663.8 million. </li>
<li>Interlink Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINK#NASDAQ">LINK</a>) stock decreased by 9.61% to $6.4. The market value of their outstanding shares is at $69.8 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARBK

BMNR

IMOS

LCFY

LINK

MASK

MOBX

SVRE

WETH

XTKG

12 Information Technology Stocks Moving In Monday's Pre-Market Session

GMS Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) (the "Company"), a leading North American specialty building products distributor, today announced the Company has entered into a definitive agreement with The Home Depot&#xAE;, the world's largest home improvement retailer, to be acquired by its specialty trade distribution subsidiary, SRS Distribution ("SRS"). Under the terms of the agreement, a subsidiary of SRS will commence a tender offer to acquire all outstanding shares of GMS common stock for $110.00 per share, for a total enterprise value (including net debt) of approximately $5.5 billion.

GMS To Be Acquired By Home Depot Subsidiary SRS Distribution In $5.5B Deal At $110 Per Share

Canaccord Genuity analyst Joseph Vafi initiates coverage on Circle Internet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) with a Buy rating and announces Price Target of $247.

Price Target

Initiation

Analyst Ratings

CRCL

Canaccord Genuity Initiates Coverage On Circle Internet Group with Buy Rating, Announces Price Target of $247

–&nbsp; Compelling PAX-D results guided Alto's acquisition of ALTO-207, designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole –
–&nbsp; Alto plans to collaborate with National Health Service, PAX-D clinical sites for the planned Phase 2b trial of ALTO-207, designed to be a potentially pivotal study; trial expected to initiate by mid-2026 –
Alto Neuroscience, Inc. ("Alto") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today highlighted The Lancet Psychiatry publication of data from the PAX-D study evaluating pramipexole in patients with treatment-resistant depression (TRD).The study was conducted by the University of Oxford and was funded by the UK government's National Institute for Health and Care Research. Results showed pramipexole augmentation of antidepressant treatment, at a target dose of 2.5mg, demonstrated a large (Cohen's d=0.87) reduction in symptoms relative to placebo at 12 weeks, but was associated with a high rate of adverse effects. The link to the online publication can be found <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanpsy%2Farticle%2FPIIS2215-0366%252825%252900194-4%2Ffulltext&amp;esheet=54283474&amp;newsitemid=20250630531248&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=e73b22777265652a6ce3ce02f737ae41">here</a>. The PAX-D study results guided Alto's acquisition of ALTO-207, a fixed-dose combination of pramipexole and the antiemetic, ondansetron.

Biotech

General

ANRO

Alto Neuroscience Highlights Lancet Psychiatry Publication Of PAX-D Study Showing Antidepressant Efficacy Of Pramipexole In TRD Despite Tolerability Limitations

TECX

Tectonic Therapeutic Added To Russell 3000 Index

Revolution Medicines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>), a biopharmaceutical oncology company focused on patient-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs, today announced the companies have entered into a clinical collaboration in multiple solid tumor settings to evaluate the safety and efficacy of each of Revolution Medicines' clinical-stage RAS(ON) inhibitors, including the multi-selective inhibitor daraxonrasib (RMC-6236), G12D-selective inhibitor zoldonrasib (RMC-9805) and G12C-selective inhibitor elironrasib (RMC-6291), in combination with Summit Therapeutics' ivonescimab, a PD-1 / VEGF bispecific antibody.
The clinical collaboration aims to evaluate these combinations across three priority tumor types including RAS mutant non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). Under the terms of the agreement, Summit Therapeutics will supply ivonescimab for clinical research and Revolution Medicines will be the study sponsor. Each company will retain commercial rights to their respective compounds, and the agreement is mutually non-exclusive.

RVMD

SMMT

Revolution Medicines And Summit Therapeutics Collaborate In Multiple Solid Tumor Settings To Evaluate Safety And Efficacy Of Each Of Revolution Medicines' Clinical-Stage RAS(ON) Inhibitors With Summit's Ivonescimab

Takeda Announces FDA Approval Of GAMMAGARD LIQUID ERC

Billionaire entrepreneur&nbsp;Mark Cuban&nbsp;has voiced his concerns over the manipulative practices of insurance companies, suggesting a need for radical changes in the healthcare sector.
What Happened: Cuban, in a post on X on Sunday, criticized insurance companies for designing plans with unaffordable deductibles. He explained that when plan holders can&#8217;t afford these deductibles, they avoid seeking care, allowing insurance companies to pocket the premiums without covering any healthcare costs.
He also highlighted how hospitals bear the financial burden when patients can&#8217;t pay, leading to inflated fees to compensate for these losses.
His post was a response to Senator&nbsp;Josh Hawley&#8216;s post, which questioned the ethics of insurance companies consulting with firms like McKinsey to design programs that exploit policyholders.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">It&#39;s worse than you know. Ins comps design plans with deductibles they know the plan holder can&#39;t afford. If the customer can never afford the deductible, they don&#39;t get care and the ins comp never has to pay for anything. They just keep the premium. If the plan holder… <a href="https://t.co/63WW363CDG">https://t.co/63WW363CDG</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1939395432368800178?ref_src=twsrc%5Etfw">June 29, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cuban suggested that Sen. Josh Hawley &#8220;freak them out and change the game&#8221;.
The Cost Plus Drugs Founder pitched a tough new proposal targeting insurance companies: Firstly, if an insurer or its subsidiary is fined by the government, it would face increasing bans from doing business with HHS—1 year for the first fine, 3 years for the second, and 5 years for the third.
Secondly, to work with the government or get plan approvals, insurers would have to publicly disclose their entire general ledger, including all subsidiary entries.
&#8220;If you got nothing to hide, hide nothing,&#8221; added Cuban,
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/tech/25/06/46161059/apple-has-the-potential-to-crush-metas-ray-ban-smart-glasses-says-ming-chi-kuo-but-the-tech-giant-ha" target="_blank" rel="noreferrer noopener">Apple Has the Potential To Crush Meta&#8217;s Ray-Ban Smart Glasses, Says Ming-Chi Kuo, But The Tech Giant Has Been &#8216;Surprisingly Slow&#8217;</a>
Why It Matters:&nbsp;Cuban&#8217;s comments come in the wake of his recent proposal to eliminate traditional insurance premiums and introduce transparent pricing in the healthcare sector. His <a href="https://www.benzinga.com/markets/25/06/45992387/mark-cuban-floats-bold-healthcare-plan-zero-premiums-to-insurance-companies-with-a-cash-pay-revoluti">proposal</a>, was sparked by increasing frustration over insurance clawbacks and rising costs.
Even previously, Cuban <a href="https://www.benzinga.com/news/topics/25/05/45711157/mark-cuban-says-taking-low-premium-high-deductible-plans-is-great-for-insurance-companies-you-know-who-its-not-good-for-you-guys">criticized </a>insurance companies for designing plans with low premiums and high deductibles, a strategy he believes is beneficial for insurance companies but detrimental to patients. In another instance, Cuban called<a href="https://www.benzinga.com/25/05/45458113/mark-cuban-blasts-health-insurance-companies-as-the-worst-of-the-worst-says-it-should-be-criminal-to-charge-5k-deductibles-to-people-making-25k"> </a>the <a href="https://www.benzinga.com/25/05/45458113/mark-cuban-blasts-health-insurance-companies-as-the-worst-of-the-worst-says-it-should-be-criminal-to-charge-5k-deductibles-to-people-making-25k">practice </a>of charging exorbitant deductibles to low-income individuals a criminal act.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://www.benzinga.com/personal-finance/tax/25/06/46012776/brace-for-higher-healthcare-premiums-in-2026-as-insurers-blame-trumps-tariffs-in-filings-to-regulators-report">Brace For Higher Healthcare Premiums In 2026 As Insurers Blame Trump&#8217;s Tariffs In Filings To Regulators: Report</a> </li>
</ul>
<ol class="wp-block-list">
<li></li>
</ol>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Mark Cuban Slams Insurers Over High Deductibles, Urges Josh Hawley To 'Change The Game' With Two-Part Plan

OPAL

OPAL Fuels Added To Russell 3000 Index

ACNT

Ascent Industries Joins Russell 2000 Index, Effective June 30, 2025, As Part Of 2025 Russell Indexes Reconstitution

On June 28, his 54th birthday, Elon Musk didn't post celebratory photos or <a href="https://www.benzinga.com/topic/elon-musk">launch a new product.</a>
Instead, he launched another blistering denunciation of President Donald Trump's sweeping tax and spending bill, calling it <a href="https://www.benzinga.com/news/politics/25/06/46159125/elon-musk-calls-trumps-megabill-political-suicide-says-it-is-utterly-insane-and-destructive-will-destroy-millions-of-jobs-in-america">"utterly insane and destructive"</a> in a post on X (formerly Twitter)—an attack that reignited a political feud and underscored a deeper ideological rift between two of the most influential figures in American public life.
The legislation in question, nicknamed the <a href="https://www.benzinga.com/news/politics/25/06/46159430/trumps-major-bill-advances-in-senate-amid-late-night-vote-salt-provision-compromise-stirs-controversy">"Big, Beautiful Bill"</a> by the Trump administration, is a nearly 1,000-page proposal that combines deep tax cuts with significant spending reductions and industry-specific subsidies. The bill, which passed the House by a narrow margin in May, is now under intense scrutiny in the Senate, where Republican leaders are racing to meet Trump's self-imposed July 4 deadline.
<ul class="wp-block-list">
<li>Read More: <a href="https://www.benzinga.com/news/education/25/06/46157568/happy-birthday-elon-musk-54-facts-and-figures-about-tesla-spacex-ceo-on-his-54th-birthday">54 Things You Might Not Know About Elon Musk</a></li>
</ul>
The Tesla and SpaceX CEO&#8217;s criticism wasn't subtle. "The latest Senate draft bill will destroy millions of jobs in America and cause immense strategic harm to our country," he wrote in an X post on June 28. "It gives handouts to industries of the past while severely damaging industries of the future".
His comments came just hours before the Senate was scheduled to vote on whether to open debate on the bill. Musk, who previously served as head of the now-defunct Department of Government Efficiency (DOGE), has been increasingly vocal in his opposition since leaving the administration in May.
Musk's latest broadside wasn&#8217;t a one-off outburst. It was the culmination of a month-long escalation that began on June 3, when Musk first labeled the legislation a <a href="https://www.benzinga.com/news/politics/25/06/45757029/elon-musk-slams-congressional-spending-bill-as-a-disgusting-abomination">"disgusting abomination"</a>. What followed was a <a href="https://www.benzinga.com/news/politics/25/06/45800612/trump-says-musk-has-trump-derangement-syndrome-as-battle-over-bill-heats-up-had-a-great-relationship-dont-know-if-we-will-anymore">public unraveling of the Musk-Trump alliance</a>, complete with televised rebukes, social media barbs, and threats to sever political and financial ties.
But beyond the spectacle lies a more consequential question: What does Musk's opposition signal about the future of U.S. economic policy—and the fragile coalition behind it?
What's In The Big, Beautiful Bill?
The legislation combines sweeping tax cuts with deep spending reductions and targeted subsidies for fossil fuels, defense, and border enforcement. It also raises the debt ceiling by $5 trillion—the largest single increase in U.S. history.
While the bill passed the House in May, it has faced turbulence in the Senate, where moderate Republicans have balked at its impact on the deficit and the rollback of clean energy incentives. Musk's intervention has only intensified that pressure.
Musk's critique aligns with concerns raised by economists and industry leaders. Jesse Jenkins, an energy systems engineer at Princeton, called the bill's energy provisions "truly so bad," noting that automakers, utilities, and manufacturers alike oppose them. The Joint Committee on Taxation estimates the bill's tax provisions alone would reduce federal revenue by more than $4 trillion over the next decade.
Read More: <a href="https://www.benzinga.com/news/politics/25/06/46160881/bernie-sanders-slams-trumps-big-beautiful-bill-as-a-gift-for-billionaires-the-most-dangerous-piece-of-legislation-in-modern-history">Bernie Sanders Slams Trump&#8217;s Bill As &#8216;The Most Dangerous Piece of Legislation In Modern History'</a>
According to the Congressional Budget Office (CBO), the bill would increase the federal deficit by more than $3 trillion over the next decade. While proponents argue that the tax cuts will spur growth, critics—including some within the GOP—warn that the deficit impact could be severe.
Musk Warns Of &#8216;Political Suicide For The Republican Party&#8217;
Musk's opposition isn't limited to clean energy. He has framed the bill as a threat to American competitiveness. "It's political suicide for the Republican Party," he wrote, citing a poll by the Tarrance Group that reportedly shows declining support for the bill among independent voters. By favoring legacy sectors like coal and oil, the outspoken entrepreneur argues, the legislation undermines innovation in AI, space, and advanced manufacturing—areas where the U.S. is competing globally.
The tech billionaire&#8217;s opposition carries weight not just because of his platform—he is the most-followed person on X—but because of his political capital. He was the largest individual donor to Trump's 2024 campaign, contributing over $250 million. He also briefly served as head of the Department of Government Efficiency (DOGE), a role in which he led aggressive reductions in the federal workforce and spending cuts.
What Happens Next?
The Senate remains divided. With a razor-thin Republican majority, any defections could derail the bill. Musk's high-profile opposition may embolden moderate GOP senators who are already uneasy about the bill's deficit impact and industry favoritism.
Meanwhile, Musk's birthday broadside has dominated headlines, shifting attention from legislative details to the broader question of who shapes economic policy in 2025: elected officials or billionaire technocrats.
As the Senate prepares for a critical vote, one thing is clear—Musk's birthday wish wasn't for cake or candles. It was for Congress to kill the bill before, in his words, it kills the economy.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46087914/teslas-europe-sales-slide-for-5th-straight-month-elon-musk-led-ev-giants-market-share-shrinks-to-1-3">Tesla&#8217;s Europe Sales Slide For 5th Straight Month: Elon Musk-led EV Giant&#8217;s Market Share Shrinks To 1.3%</a></li>
</ul>
Photo: Shutterstock

Economics

Elon Musk's Birthday Wish: Kill The Bill Before It Kills The Economy

MDAI

Spectral AI Submits De Novo 510k Marketing Clearance Application To FDA For DeepView System

Seaport Global analyst Jeff Cantwell initiates coverage on Chime Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHYM#NASDAQ">CHYM</a>) with a Buy rating and announces Price Target of $37.

CHYM

Seaport Global Initiates Coverage On Chime Financial with Buy Rating, Announces Price Target of $37

Press Releases

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

Earnings

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference

Health Care

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference

Comments

Apogee Therapeutics

Unusual Options Activity for

ニュース

パートナーシップ

ベンジンガ・グローバル